Skip to main content
Top
Published in: Endocrine 1/2017

01-01-2017 | Original Article

The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism

Authors: Melia Karakose, Mustafa Caliskan, Muyesser Sayki Arslan, Taner Demirci, Suleyman Karakose, Erman Cakal

Published in: Endocrine | Issue 1/2017

Login to get access

Abstract

Purpose

Primary hyperparathyroidism has been associated with increased incidence of morbidity and mortality of the cardiovascular system. The etiopathogenetic mechanisms underlying this association are still not completely clear. Accumulating evidence suggested that a disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS) has a role in the development of inflammation and atherosclerosis. In this study, we aimed to determine whether there is a change in serum levels of ADAMTS1, ADAMTS4, carotid intima-media thickness, and cardiovascular risk score after the surgery and also whether there is a relationship between ADAMTS levels and cardiovascular risk score in hypercalcemic primary hyperparathyroidism patients.

Methods

The study included the 48 consecutive newly diagnosed patients with primary hyperparathyroidism. The patients were evaluated before and six months after parathyroidectomy. The Framingham score is used to calculate cardiovascular risk. Serum ADAMTS levels were determined by a human enzyme-linked immunoassay in all subjects.

Results

The fasting glucose, fasting insulin levels and HOMA values were decreased significantly in all patients after surgery compared to the pretreatment values (p < 0.05). ADAMTS1, ADAMTS4, and carotid intima-media thickness levels were significantly lower after surgical correction of primary hyperparathyroidism compared to the preoperative values (p < 0.05). cardiovascular risk score was decreased after parathyroidectomy however, the difference were not statistical significant (p > 0.05). There were statistically significant relationship between cardiovascular risk score and waist/hip ratio, calcium, LDL-cholesterol, carotid intima-media thickness, ADAMTS4 values.

Conclusion

Based on the results of the present study, fasting glucose, fasting insulin levels, ADAMTS1, ADAMTS4, and carotid intima-media thickness might be an additional parameters during the management of patients with primary hyperparathyroidism, since these factors might improve after surgery.
Literature
1.
go back to reference S. Ljunghall, H. Lithell, B. Vessby et al., Glucose and lipoprotein metabolism in primary hyperparathyroidism. Effects of parathyroidectomy. Acta. Endocrinol. (Copenh). 89, 580–589 (1978)PubMed S. Ljunghall, H. Lithell, B. Vessby et al., Glucose and lipoprotein metabolism in primary hyperparathyroidism. Effects of parathyroidectomy. Acta. Endocrinol. (Copenh). 89, 580–589 (1978)PubMed
2.
go back to reference M. Procopio, G. Magro, F. Cesario et al., The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet. Med. 19, 958–961 (2002)CrossRefPubMed M. Procopio, G. Magro, F. Cesario et al., The oral glucose tolerance test reveals a high frequency of both impaired glucose tolerance and undiagnosed type 2 diabetes mellitus in primary hyperparathyroidism. Diabet. Med. 19, 958–961 (2002)CrossRefPubMed
3.
go back to reference S. Ljunghall, M. Palmér, G. Å kerström et al., Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. Eur. J. Clin. Invest. 13, 373–377 (1983)CrossRefPubMed S. Ljunghall, M. Palmér, G. Å kerström et al., Diabetes mellitus, glucose tolerance and insulin response to glucose in patients with primary hyperparathyroidism before and after parathyroidectomy. Eur. J. Clin. Invest. 13, 373–377 (1983)CrossRefPubMed
4.
go back to reference M.J. Bolland, A.B. Grey, G.D. Gamble et al., Association between primary hyperparathyroidism and increased body weight: a metaanalysis. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRef M.J. Bolland, A.B. Grey, G.D. Gamble et al., Association between primary hyperparathyroidism and increased body weight: a metaanalysis. Clin. Endocrinol. Metab. 90, 1525–1530 (2005)CrossRef
5.
go back to reference G. Hedbäck, A. Odén, Death risk factor analysis in primary hyperparathyroidism. Eur. J. Clin. Invest. 28, 1011–1018 (1998)CrossRef G. Hedbäck, A. Odén, Death risk factor analysis in primary hyperparathyroidism. Eur. J. Clin. Invest. 28, 1011–1018 (1998)CrossRef
6.
go back to reference G. Hedbäck, A. Odén, Increased risk of death from primary hyperparathyroidism – an update. Eur. J. Clin. Invest. 28, 271–276 (1998)CrossRef G. Hedbäck, A. Odén, Increased risk of death from primary hyperparathyroidism – an update. Eur. J. Clin. Invest. 28, 271–276 (1998)CrossRef
7.
go back to reference S. Valdemarsson, P. Lindblom, A. Bergenfelz, Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J. Intern. Med. 244, 241–249 (1998)CrossRefPubMed S. Valdemarsson, P. Lindblom, A. Bergenfelz, Metabolic abnormalities related to cardiovascular risk in primary hyperparathyroidism: effects of surgical treatment. J. Intern. Med. 244, 241–249 (1998)CrossRefPubMed
8.
go back to reference E. Osto, F. Fallo, M.R. Pelizzo et al., Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)CrossRefPubMed E. Osto, F. Fallo, M.R. Pelizzo et al., Coronary microvascular dysfunction induced by primary hyperparathyroidism is restored after parathyroidectomy. Circulation 126, 1031–1039 (2012)CrossRefPubMed
9.
go back to reference M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008)CrossRefPubMed M.D. Walker, S.J. Silverberg, Cardiovascular aspects of primary hyperparathyroidism. J. Endocrinol. Invest. 31, 925–931 (2008)CrossRefPubMed
10.
go back to reference E. Hagström, E. Lundgren, H. Mallmin et al., Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism. J. Intern. Med. 259, 191–198 (2006)CrossRef E. Hagström, E. Lundgren, H. Mallmin et al., Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism. J. Intern. Med. 259, 191–198 (2006)CrossRef
11.
go back to reference B. Lacour, J.B. Roullet, A.M. Liagre et al., Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am. J. Kidney. Dis. 8, 422–429 (1986)CrossRefPubMed B. Lacour, J.B. Roullet, A.M. Liagre et al., Serum lipoprotein disturbances in primary and secondary hyperparathyroidism and effects of parathyroidectomy. Am. J. Kidney. Dis. 8, 422–429 (1986)CrossRefPubMed
12.
go back to reference T. Christensson, K. Einarsson, Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. Clin. Chim. Acta. 78, 411–415 (1977)CrossRefPubMed T. Christensson, K. Einarsson, Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism. Clin. Chim. Acta. 78, 411–415 (1977)CrossRefPubMed
13.
go back to reference S.J. Silverberg, E. Shane, T.P. Jacobs et al., A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249–1255 (1999)CrossRefPubMed S.J. Silverberg, E. Shane, T.P. Jacobs et al., A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249–1255 (1999)CrossRefPubMed
14.
go back to reference A. Sitges-Serra, M. Girvent, J.A. Pereira et al., Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy. World J. Surg. 28, 1148–1152 (2004)CrossRefPubMed A. Sitges-Serra, M. Girvent, J.A. Pereira et al., Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy. World J. Surg. 28, 1148–1152 (2004)CrossRefPubMed
15.
go back to reference J. Monchik Normocalcemic hyperparathyroidism. In Textbook of Endocrine Surgery, 424–429 (2005) J. Monchik Normocalcemic hyperparathyroidism. In Textbook of Endocrine Surgery, 424–429 (2005)
16.
go back to reference R. Stocker, J.F. Keaney Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed R. Stocker, J.F. Keaney Jr., Role of oxidative modifications in atherosclerosis. Physiol. Rev. 84, 1381–1478 (2004)CrossRefPubMed
17.
18.
go back to reference K.J. Williams, Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr. Opin. Lipidol. 12, 477–487 (2001)CrossRefPubMed K.J. Williams, Arterial wall chondroitin sulfate proteoglycans: diverse molecules with distinct roles in lipoprotein retention and atherogenesis. Curr. Opin. Lipidol. 12, 477–487 (2001)CrossRefPubMed
19.
go back to reference T.N. Wight, Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 14, 617–623 (2002)CrossRefPubMed T.N. Wight, Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 14, 617–623 (2002)CrossRefPubMed
20.
go back to reference R.C. Salter, T.G. Ashlin, A.P. Kwan et al., ADAMTS proteases: key roles in atherosclerosis? J. Mol. Med. 88, 1203–1211 (2010)CrossRefPubMed R.C. Salter, T.G. Ashlin, A.P. Kwan et al., ADAMTS proteases: key roles in atherosclerosis? J. Mol. Med. 88, 1203–1211 (2010)CrossRefPubMed
23.
go back to reference T. Wight, M. Merrilees, Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ. Res. 94, 1158–1167 (2004)CrossRefPubMed T. Wight, M. Merrilees, Proteoglycans in atherosclerosis and restenosis: key roles for versican. Circ. Res. 94, 1158–1167 (2004)CrossRefPubMed
24.
go back to reference G. Committee, 2003 European society ve hypertension–European society of cardiology guidelines fort the management of arteriel hypertension. J. Hypertens. 21, 1011–1053 (2003)CrossRef G. Committee, 2003 European society ve hypertension–European society of cardiology guidelines fort the management of arteriel hypertension. J. Hypertens. 21, 1011–1053 (2003)CrossRef
25.
go back to reference D.R. Matthews, J.P. Hosker, A.S. Rudenski et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)CrossRefPubMed D.R. Matthews, J.P. Hosker, A.S. Rudenski et al., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28, 412–419 (1985)CrossRefPubMed
26.
go back to reference E. Orwoll, J.B. Blank, E. Barrett-Connor et al., Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp. Clin. Trials 26, 569–585 (2005)CrossRefPubMed E. Orwoll, J.B. Blank, E. Barrett-Connor et al., Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study—a large observational study of the determinants of fracture in older men. Contemp. Clin. Trials 26, 569–585 (2005)CrossRefPubMed
27.
go back to reference R.B. D’Agostino Sr, R.S. Vasan, M.J. Pencina et al., General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743–753 (2008)CrossRefPubMed R.B. D’Agostino Sr, R.S. Vasan, M.J. Pencina et al., General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743–753 (2008)CrossRefPubMed
28.
go back to reference Z. Galis, G. Sukhova, M. Lark et al., Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994)CrossRefPubMedPubMedCentral Z. Galis, G. Sukhova, M. Lark et al., Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. 94, 2493–2503 (1994)CrossRefPubMedPubMedCentral
29.
go back to reference L. Chen, L. Yang, Y. Zha et al., Association of serum a disintegrin and metalloproteinase with thrombospodin motif 4 levels with the presence and severity of coronary artery disease. Coron. Artery Dis. 22, 570–576 (2011)CrossRefPubMed L. Chen, L. Yang, Y. Zha et al., Association of serum a disintegrin and metalloproteinase with thrombospodin motif 4 levels with the presence and severity of coronary artery disease. Coron. Artery Dis. 22, 570–576 (2011)CrossRefPubMed
30.
go back to reference Y. Zha, Y. Chen, F. Xu et al., ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes. Biomed. Pharmacother. 64, 160–164 (2010)CrossRefPubMed Y. Zha, Y. Chen, F. Xu et al., ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes. Biomed. Pharmacother. 64, 160–164 (2010)CrossRefPubMed
31.
go back to reference A. Jönsson-Rylander, T. Nilsson, R. Fritsche-Danielson et al., Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of Versican. Arterioscler. Thromb. Vasc. Biol. 25, 180–185 (2005)PubMed A. Jönsson-Rylander, T. Nilsson, R. Fritsche-Danielson et al., Role of ADAMTS-1 in atherosclerosis: remodeling of carotid artery, immunohistochemistry, and proteolysis of Versican. Arterioscler. Thromb. Vasc. Biol. 25, 180–185 (2005)PubMed
32.
go back to reference S. Kumar, A.O. Olukoga, C. Gordon et al., Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin. Endocrinol. (Oxf). 40, 47–53 (1994)CrossRefPubMed S. Kumar, A.O. Olukoga, C. Gordon et al., Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism. Clin. Endocrinol. (Oxf). 40, 47–53 (1994)CrossRefPubMed
33.
go back to reference S. Norenstedt, Y. Pernow, K. Brismar et al., Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur. J. Endocrinol. 169, 795–804 (2013)CrossRefPubMedPubMedCentral S. Norenstedt, Y. Pernow, K. Brismar et al., Primary hyperparathyroidism and metabolic risk factors, impact of parathyroidectomy and vitamin D supplementation, and results of a randomized double-blind study. Eur. J. Endocrinol. 169, 795–804 (2013)CrossRefPubMedPubMedCentral
34.
go back to reference S.J. Silverberg, B.L. Clarke, M. Peacock et al., Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. Clin. Endocrinol. Metab. 99, 3580–3594 (2014)CrossRef S.J. Silverberg, B.L. Clarke, M. Peacock et al., Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. Clin. Endocrinol. Metab. 99, 3580–3594 (2014)CrossRef
35.
go back to reference J. Rosa, I. Raska Jr, D. Wichterle et al., Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens. Res. 34, 296–300 (2011)CrossRefPubMed J. Rosa, I. Raska Jr, D. Wichterle et al., Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertens. Res. 34, 296–300 (2011)CrossRefPubMed
36.
go back to reference G. Schillaci, G. Pucci, M. Pirro et al., Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218, 96–101 (2011)CrossRefPubMed G. Schillaci, G. Pucci, M. Pirro et al., Large-artery stiffness: a reversible marker of cardiovascular risk in primary hyperparathyroidism. Atherosclerosis 218, 96–101 (2011)CrossRefPubMed
Metadata
Title
The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism
Authors
Melia Karakose
Mustafa Caliskan
Muyesser Sayki Arslan
Taner Demirci
Suleyman Karakose
Erman Cakal
Publication date
01-01-2017
Publisher
Springer US
Published in
Endocrine / Issue 1/2017
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1175-3

Other articles of this Issue 1/2017

Endocrine 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.